45 completed, 16 unknown, 7 terminated, 1 not yet recruiting. 70 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 70 | Completed 45, Unknown 16, Terminated 7, Not yet recruiting 1, Withdrawn 1 |
Follow glimepiride: new trials by email Literature Review of glimepiride trials Research Report on glimepiride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients empagliflozin 10mg, Glimepiride 1mg - Diabete Type 2 | Phase 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 200 | 2026-03-01 | 2026-01-26 |
| Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes SGLT2 inhibitor, Glimepiride - Diabetes Mellitus, Cellular Senescence | Phase 4 | Unknown | Yonsei University | 92 | 2023-06-01 | 2024-05-09 |
| The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes Glimepiride, Sitagliptin - Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes | Phase 4 | Unknown | Peking University People's Hospital | 192 | 2022-01-01 | 2022-05-23 |
| Fenofibrate Versus Curcumin in Type 2 Diabetic Patients Glimepiride Tablets, glimepiride plus fenofibrate, glimepiride plus curcumin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Rehab Werida | 60 | 2020-11-01 | 2022-03-04 |
| Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus | Phase 4 | Unknown | Peking Union Medical College Hospital | 180 | 2020-03-02 | 2020-02-27 |
| Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes Gemigliptin, Glimepiride - Ejection Fraction | Phase 4 | Unknown | Seoul National University Bundang Hospital | 80 | 2020-01-01 | 2023-03-08 |
| Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD Vildagliptin 50 mg Oral Tablet, Metformin 1000 mg Oral Tablet, Glimepiride upto 4 mg Oral Tablet - Coronary Artery Disease, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Damanhour University | 80 | 2018-10-08 | 2023-06-13 |
| Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema Empagliflozin, Glimepiride, Empagliflozin placebo - Diabetes Mellitus, Type II | Phase 4 | Terminated | Hannover Medical School | 6 | 2017-06-12 | 2018-09-27 |
| A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria metformin, ipragliflozin, glimepiride - Type 2 Diabetes Mellitus | Phase 4 | Terminated | Astellas Pharma Korea, Inc. | 33 | 2017-04-25 | 2024-11-08 |
| Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan Metformin and Glimepiride (Low Dosage), Metformin and Vildagliptin (Low Dosage), Metformin and Insulin Glargine U100 (Low Dosage) - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Jordan | 687 | 2017-02-14 | 2020-02-11 |
| Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Dapagliflozin, Glimepiride - Type2 Diabetes, Cardiovascular Diseases | Phase 4 | Completed | University of Michigan | 45 | 2017-01-12 | 2020-10-22 |
| Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction. Dapagliflozin 10 mg, Glimepiride 4 mg - Diabetes Mellitus, Type 2 | Phase 4 | Unknown | IInstituto Gallego de Medicina Vascular | 159 | 2016-12-13 | 2017-03-29 |
| Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan Canagliflozin, Repaglinide, Pioglitazone - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Leicester | 25 | 2016-07-01 | 2020-01-30 |
| SGLT2 Inhibition and Left Ventricular Mass Empagliflozin, Glimepiride - Diabetes Mellitus Type 2 | Phase 4 | Terminated | Hannover Medical School | 7 | 2016-04-27 | 2019-03-22 |
| Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) Empagliflozin 10 MG, Glimepiride 2 mg - Type 2 Diabetes, Cardiovascular Risk Factor | Phase 4 | Completed | University of Catanzaro | 26 | 2016-04-01 | 2023-01-18 |
| Foxiga Korea Local Phase 4 Study Dapagliflozin, Glimepiride - Diabetes Mellitus, Type 2 | Phase 4 | Completed | AstraZeneca | 125 | 2016-01-05 | 2019-08-20 |
| Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination Glimepiride, Alogliptin 25Mg Tab, Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet - Type 2 Diabetes Mellitus | Phase 4 | Unknown | Seoul National University Hospital | 99 | 2015-12-31 | 2020-10-22 |
| SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Tofogliflozin, Glimepiride - Non-alcoholic Fatty Liver Disease | Phase 4 | Completed | Kanazawa University | 40 | 2015-11-11 | 2021-07-02 |
| Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Dapagliflozin, Saxagliptin, Glimepiride - Type 2 Diabetes Mellitus, Inadequate Glycaemic Control | Phase 4 | Completed | AstraZeneca | 939 | 2015-09-21 | 2019-03-26 |
| Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Sitagliptin, Glimepiride, Sitagliptin-Placebo - Diabetes Mellitus Type 2 | Phase 4 | Terminated | GWT-TUD GmbH | 4 | 2015-09-01 | 2019-02-27 |
Showing 20 of 70. Sign in to see all of them.
Diabetes Mellitus, Type 2 (60) · Diabetes Mellitus (11) · Insulin Resistance (5) · Hypoglycemia (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetic Ketoacidosis (1) · Diabetic Nephropathies (1) · Fasting (1) · Hyperglycemia (1) · Hyperglycemic Hyperosmolar Nonketotic Coma (1) · Non-alcoholic Fatty Liver Disease (1)
Sanofi (10) · AstraZeneca (3) · Handok Inc. (3) · Novo Nordisk A/S (3) · Seoul National University Bundang Hospital (3) · Hannover Medical School (2) · Laboratorios Silanes S.A. de C.V. (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Seoul National University Hospital (2) · Ajou University School of Medicine (1) · Amsterdam UMC, location VUmc (1) · Astellas Pharma Korea, Inc. (1) · Chong Kun Dang Pharmaceutical (1) · Damanhour University (1)
South Korea (19) · Germany (11) · China (6) · Mexico (6) · Japan (5) · United States (5) · Austria (4) · Czechia (4) · France (4) · Italy (4) · Poland (4) · Spain (4) · United Kingdom (4) · Brazil (3) · Egypt (3)
Ji Young Ahn (2) · Alfonso Calle, MD (1) · Alvaro Hermida, MD, PhD (1) · Amelie Pielen, MD (1) · Ayman A. Zayed, MD (1) · BW Lee (1) · Dalong Zhu, MD, PhD (1) · Dario Giugliano, MD PHD (1)
PMID 16612330, PMID 17115351, PMID 19821654, PMID 20363044, PMID 20388897, PMID 21206136, PMID 22025647, PMID 22775317, PMID 23305037, PMID 23998560, PMID 24026560, PMID 24445656, PMID 24614911, PMID 24957785, PMID 25422771, PMID 25761977, PMID 26003889, PMID 26105582, PMID 27229178, PMID 27823868, PMID 28271251, PMID 28671753, PMID 28735818, PMID 29766812, PMID 29947099, PMID 30520221, PMID 31013312, PMID 31339011, PMID 31956961, PMID 32900785, PMID 33002553, PMID 33166419, PMID 34024686, PMID 34305809, PMID 35894933, PMID 37435938, PMID 40481568, PMID 41665872, PMID 42530605
2016 (1)